Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast

Clinical trial NCT03812393 · UNKNOWN

Trial details

NCT number: NCT03812393
Sponsor: West Cancer Center
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Triple Negative Breast Cancer Early-stage Breast Cancer HER2-positive Breast Cancer

Start date: 2019-06-21
Primary completion: 2024-12-15
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.